Publication:


abstract

Background  The reported efficacy and safety of some biologic agents for psoriasis vary between Caucasians and Asians. Few reports of Etanercept exist in psoriasis patients within the Asia-Pacific region. Objectives  The study aims to report our clinical experience of etanercept in the treatment of patients with moderate-to-severe psoriasis in Taiwan. Methods  A retrospective analysis of 59 patients with moderate-to-severe psoriasis who received etanercept was conducted in a tertiary referral center. Results  Etanercept therapy resulted in a reduction of mean Psoriasis Area and Severity Index (PASI) of 47% at week 12 and 61% at week 24. After 12 weeks of treatment, 48%, 26%, and 3.4% of the patients achieved at least PASI50, 75 and 90 response, respectively. At week 24, the proportion of patients achieving at least PASI50, 75 and 90 response was 59%, 37%, and 14%, respectively. Etanercept efficacy in achieving PASI75 improvement was, however, lower than that reported in previous pivotal placebo-controlled trials. No cases of active tuberculosis, viral hepatitis or malignancies were observed during the observation period. Conclusion  Our case series demonstrated the efficacy and safety of etanercept for the management of moderate-to-severe psoriasis in Taiwan.

© 2012 The International Society of Dermatology.

Related Articles
Review Etanercept and efalizumab for the treatment of psoriasis: a systematic review.
Health Technol Assess. 2006
Review Etanercept and efalizumab for the treatment of psoriasis: a systematic review.
Woolacott N, Hawkins N, Mason A, Kainth A, Khadjesari Z, Vergel YB, Misso K, Light K, Chalmers R, Sculpher M, et al. Health Technol Assess. 2006 Nov; 10(46):1-233, i-iv.
Once weekly administration of etanercept 50 mg is efficacious and well tolerated in patients with moderate-to-severe plaque psoriasis: a randomized controlled trial with open-label extension.
Br J Dermatol. 2008
Once weekly administration of etanercept 50 mg is efficacious and well tolerated in patients with moderate-to-severe plaque psoriasis: a randomized controlled trial with open-label extension.
van de Kerkhof PC, Segaert S, Lahfa M, Luger TA, Karolyi Z, Kaszuba A, Leigheb G, Camacho FM, Forsea D, Zang C, et al. Br J Dermatol. 2008 Nov; 159(5):1177-85. Epub 2008 Jul 31.
Treating psoriasis with etanercept in italian clinical practice: prescribing practices and duration of remission following discontinuation.
Clin Drug Investig. 2010
Treating psoriasis with etanercept in italian clinical practice: prescribing practices and duration of remission following discontinuation.
Arcese A, Aste N, Bettacchi A, Camplone G, Cantoresi F, Caproni M, D'Amico D, Fabbri P, Filosa G, Galluccio A, et al. Clin Drug Investig. 2010; 30(8):507-16.
Efficacy and safety results from a phase III, randomized controlled trial comparing the safety and efficacy of briakinumab with etanercept and placebo in patients with moderate to severe chronic plaque psoriasis.
Br J Dermatol. 2011
Efficacy and safety results from a phase III, randomized controlled trial comparing the safety and efficacy of briakinumab with etanercept and placebo in patients with moderate to severe chronic plaque psoriasis.
Strober BE, Crowley JJ, Yamauchi PS, Olds M, Williams DA. Br J Dermatol. 2011 Sep; 165(3):661-8. Epub 2011 Jul 28.
Review An overview of infliximab, etanercept, efalizumab, and alefacept as biologic therapy for psoriasis.
Clin Ther. 2003
Review An overview of infliximab, etanercept, efalizumab, and alefacept as biologic therapy for psoriasis.
Weinberg JM. Clin Ther. 2003 Oct; 25(10):2487-505.